Celanese Announces Commercial Launch of Glaukos' iDose® TR (Travoprost Intracameral Implant) Using Celanese's VitalDose® Ethylene Vinyl Acetate (EVA)

Dear Subscriber,

New Press Release from Celanese:

Celanese Announces Commercial Launch of Glaukos' iDose® TR (Travoprost Intracameral Implant) Using Celanese's VitalDose® Ethylene Vinyl Acetate (EVA)

DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, announced the launch of iDose® TR by Glaukos Corporation using Celanese’s VitalDose® EVA to provide sustained drug release for the treatment of glaucoma. The majority of glaucoma and ocular hypertension patients are non-compliant with topical medication use due to complex dosing ...

To update your preferences, click here. To unsubscribe from all Celanese mailing lists, click here.